Clark W F, Lindsay R M, Cattran D C, Chodirker W B, Barnes C C, Linton A L
Can Med Assoc J. 1981 Jul 15;125(2):171-4.
Twelve patients with systemic lupus erythematosus and biopsy-proved diffuse proliferative glomerulonephritis were randomly allocated to a control group (to continue receiving conventional therapy only) or to a plasmapheresis group (to receive conventional therapy along with one 4-I plasma exchange a month). The six patients treated with plasmapheresis had better preservation of renal function, reduced disease activity, fewer admissions to hospital and less need for steroid and immunosuppressive therapy than the six control patients. The patients treated with plasmapheresis also showed evidence of reduced immunologic activity and had no side effects attributable to the plasma exchange. These results suggest that monthly plasma exchange should be assessed in a controlled randomized trial as a possible therapeutic adjunct in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis.
12例经活检证实为弥漫性增殖性肾小球肾炎的系统性红斑狼疮患者被随机分为对照组（仅继续接受传统治疗）或血浆置换组（在接受传统治疗的同时每月进行1次4升血浆置换）。与6例对照患者相比，接受血浆置换治疗的6例患者肾功能保存更好，疾病活动度降低，住院次数减少，对类固醇和免疫抑制治疗的需求也更少。接受血浆置换治疗的患者还显示出免疫活性降低的迹象，且没有可归因于血浆置换的副作用。这些结果表明，应在一项对照随机试验中评估每月进行血浆置换作为系统性红斑狼疮和弥漫性增殖性肾小球肾炎患者可能的治疗辅助手段。
